LIVIVO - Search results -

Search results

Result 1 - 10 of total 11

Search options

Article ; Online: The role of cilia in the regulation of bile flow.

Larusso, Nicholas F / Masyuk, Tetyana V

2011 Volume 29, Issue 1, Page(s) 6–12

Abstract: Cholangiocytes, the epithelial cells lining intrahepatic bile ducts, are ciliated cells. Each cholangiocyte has a primary cilium consisting of (i) a microtubule-based axoneme and (ii) the basal body, centriole-derived, microtubule-organizing center from ... ...

Abstract	Cholangiocytes, the epithelial cells lining intrahepatic bile ducts, are ciliated cells. Each cholangiocyte has a primary cilium consisting of (i) a microtubule-based axoneme and (ii) the basal body, centriole-derived, microtubule-organizing center from which the axoneme emerges. Primary cilia in cholangiocytes were described decades ago, but their physiological and pathophysiological significance remained unclear until recently. We now recognize that cholangiocyte cilia extend from the apical plasma membrane into the bile duct lumen and, as such, are ideally positioned to detect changes in bile flow, bile composition and bile osmolality. These sensory organelles act as cellular antennae that can detect and transmit signals that influence cholangiocyte function. Indeed, recent data show that cholangiocyte primary cilia can activate intracellular signaling pathways when they sense modifications in the flow, molecular constituents and osmolarity of bile. Their ability to sense and transmit signals depends on the participation of a growing number of specific ciliary-associated proteins that act as receptors, channels and transporters. Cholangiocyte cilia, in addition to being important in normal biliary physiology, likely contribute to the cholangiopathies when their normal structure or function is disturbed. Indeed, the polycystic liver diseases that occur in combination with autosomal dominant and recessive polycystic kidney disease (i.e. ADPKD and ARPKD) are two important examples of such conditions. Recent insights into the role of cholangiocyte cilia in cystic liver disease using in vitro and animal models have already resulted in clinical trials that have influenced the management of cystic liver disease.
MeSH term(s)	Animals ; Bile/metabolism ; Bile Ducts/cytology ; Bile Ducts/metabolism ; Biological Transport ; Cilia/metabolism ; Cilia/ultrastructure ; Humans ; Models, Biological
Language	English
Publishing date	2011-06-17
Publishing country	Switzerland
Document type	Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
ZDB-ID	632798-9
ISSN	1421-9875 ; 0257-2753
ISSN (online)	1421-9875
ISSN	0257-2753
DOI	10.1159/000324121
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 1853: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾

Article ; Online: MicroRNAs and benign biliary tract diseases.

Gradilone, Sergio A / O'Hara, Steven P / Masyuk, Tetyana V / Pisarello, Maria Jose Lorenzo / LaRusso, Nicholas F

Seminars in liver disease

2015 Volume 35, Issue 1, Page(s) 26–35

Abstract: Cholangiocytes, the epithelial cells lining the biliary tree, represent only a small portion of the total liver cell population (3-5%), but they are responsible for the secretion of up to 40% of total daily bile volume. In addition, cholangiocytes are ... ...

Abstract	Cholangiocytes, the epithelial cells lining the biliary tree, represent only a small portion of the total liver cell population (3-5%), but they are responsible for the secretion of up to 40% of total daily bile volume. In addition, cholangiocytes are the target of a diverse group of liver diseases affecting the biliary tract, the cholangiopathies; for most of these conditions, the pathological mechanisms are unclear. MicroRNAs (miRNAs) are small, noncoding RNAs that posttranscriptionally regulate gene expression. Thus, it is not surprising that altered miRNA profiles underlie the dysregulation of several proteins involved in the pathobiology of the cholangiopathies, as well as showing promise as diagnostic and prognostic tools. Here the authors review recent work relevant to the role of miRNAs in the etiopathogenesis of several of the cholangiopathies (i.e., fibroinflammatory cholangiopathies and polycystic liver diseases), discuss their value as prognostic and diagnostic tools, and provide suggestions for further research.
MeSH term(s)	Bile Duct Neoplasms/genetics ; Bile Duct Neoplasms/metabolism ; Bile Ducts, Intrahepatic ; Biliary Atresia/genetics ; Biliary Atresia/metabolism ; Biliary Tract/cytology ; Biliary Tract Diseases/genetics ; Biliary Tract Diseases/metabolism ; Cholangiocarcinoma/genetics ; Cholangiocarcinoma/metabolism ; Cholangitis, Sclerosing/genetics ; Cholangitis, Sclerosing/metabolism ; Epithelial Cells/cytology ; Epithelial Cells/metabolism ; Humans ; Liver Cirrhosis, Biliary/genetics ; Liver Cirrhosis, Biliary/metabolism ; MicroRNAs/genetics ; MicroRNAs/metabolism
Chemical Substances	MicroRNAs
Language	English
Publishing date	2015-02
Publishing country	United States
Document type	Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't ; Review
ZDB-ID	603177-8
ISSN	1098-8971 ; 0272-8087
ISSN (online)	1098-8971
ISSN	0272-8087
DOI	10.1055/s-0034-1397346
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Full text

In stock of ZB MED Cologne/Königswinter

Zs.A 1752: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article: The Role of Cilia in the Regulation of Bile Flow

LaRusso, Nicholas F. / Masyuk, Tetyana V.

Digestive Diseases

2011 Volume 29, Issue 1, Page(s) 6–12

Institution	Miles and Shirley Fiterman Center for Digestive Diseases, Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, Minn., USA
Abstract	Cholangiocytes, the epithelial cells lining intrahepatic bile ducts, are ciliated cells. Each cholangiocyte has a primary cilium consisting of (i) a microtubule-based axoneme and (ii) the basal body, centriole-derived, microtubule-organizing center from which the axoneme emerges. Primary cilia in cholangiocytes were described decades ago, but their physiological and pathophysiological significance remained unclear until recently. We now recognize that cholangiocyte cilia extend from the apical plasma membrane into the bile duct lumen and, as such, are ideally positioned to detect changes in bile flow, bile composition and bile osmolality. These sensory organelles act as cellular antennae that can detect and transmit signals that influence cholangiocyte function. Indeed, recent data show that cholangiocyte primary cilia can activate intracellular signaling pathways when they sense modifications in the flow, molecular constituents and osmolarity of bile. Their ability to sense and transmit signals depends on the participation of a growing number of specific ciliary-associated proteins that act as receptors, channels and transporters. Cholangiocyte cilia, in addition to being important in normal biliary physiology, likely contribute to the cholangiopathies when their normal structure or function is disturbed. Indeed, the polycystic liver diseases that occur in combination with autosomal dominant and recessive polycystic kidney disease (i.e. ADPKD and ARPKD) are two important examples of such conditions. Recent insights into the role of cholangiocyte cilia in cystic liver disease using in vitro and animal models have already resulted in clinical trials that have influenced the management of cystic liver disease.
Keywords	Cholangiocyte ; Cilia ; Cholangiociliopathies ; Mechanosensation ; Chemosensation ; Osmosensation
Language	English
Publishing date	2011-06-17
Publisher	S. Karger AG
Publishing place	Basel, Switzerland
Document type	Article
Note	Metabolism and Transport of Bile Acids
ZDB-ID	632798-9
ISBN	978-3-8055-9727-2 ; 978-3-8055-9728-9 ; 3-8055-9727-4 ; 3-8055-9728-2
ISSN	1421-9875 ; 0257-2753
ISSN (online)	1421-9875
ISSN	0257-2753
DOI	10.1159/000324121
Database	Karger publisher's database

In stock of ZB MED Cologne/Königswinter

Zs.A 1853: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: MicroRNAs in Cholangiopathies.

O'Hara, Steven P / Gradilone, Sergio A / Masyuk, Tetyana V / Tabibian, James H / LaRusso, Nicholas F

Current pathobiology reports

2014 Volume 2, Issue 3, Page(s) 133–142

Abstract: Cholangiocytes, the cells lining bile ducts, comprise a small fraction of the total cellular component of the liver, yet perform the essential role of bile modification and transport of biliary and blood constituents. Cholangiopathies are a diverse group ...

Abstract	Cholangiocytes, the cells lining bile ducts, comprise a small fraction of the total cellular component of the liver, yet perform the essential role of bile modification and transport of biliary and blood constituents. Cholangiopathies are a diverse group of biliary disorders with the cholangiocyte as the target cell; the etiopathogenesis of most cholangiopathies remains obscure. MicroRNAs are small non-coding RNAs that post-transcriptionally regulate gene expression. These small RNAs may not only be involved in the etiopathogenesis of disease, but are showing promise as diagnostic and prognostic tools. In this brief review, we summarize recent work regarding the role of microRNAs in the etiopathogenesis of several cholangiopathies, and discuss their utility as prognostic and diagnostic tools.
Language	English
Publishing date	2014-07-29
Publishing country	United States
Document type	Journal Article
ISSN	2167-485X
ISSN	2167-485X
DOI	10.1007/s40139-014-0048-9
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Details ▾
- Full text online
- Order with fees

Article ; Online: The zebrafish as a model to study polycystic liver disease.

Tietz Bogert, Pamela S / Huang, Bing Q / Gradilone, Sergio A / Masyuk, Tetyana V / Moulder, Gary L / Ekker, Stephen C / Larusso, Nicholas F

Zebrafish

2013 Volume 10, Issue 2, Page(s) 211–217

Abstract: In the polycystic liver diseases (PLD), genetic defects initiate the formation of cysts in the liver and kidney. In rodent models of PLD (i.e., the PCK rat and Pkd2(WS25/-) mouse), we have studied hepatorenal cystic disease and therapeutic approaches. In ...

Abstract	In the polycystic liver diseases (PLD), genetic defects initiate the formation of cysts in the liver and kidney. In rodent models of PLD (i.e., the PCK rat and Pkd2(WS25/-) mouse), we have studied hepatorenal cystic disease and therapeutic approaches. In this study, we employed zebrafish injected with morpholinos against genes involved in the PLD, including sec63, prkcsh, and pkd1a. We calculated the liver cystic area, and based on our rodent studies, we exposed the embryos to pasireotide [1 μM] or vitamin K3 [100 μM] and assessed the endoplasmic reticulum (ER) in cholangiocytes in embryos treated with 4-phenylbutyrate (4-PBA). Our results show that (a) morpholinos against sec63, prkcsh, and pkd1a eliminate expression of the respective proteins; (b) phenotypic body changes included curved tail and the formation of hepatic cysts in zebrafish larvae; (c) exposure of embryos to pasireotide inhibited hepatic cystogenesis in the zebrafish models; and (d) exposure of embryos to 4-PBA resulted in the ER in cholangiocytes resolving from a curved to a smooth appearance. Our results suggest that the zebrafish model of PLD may provide a means to screen drugs that could inhibit hepatic cystogenesis.
MeSH term(s)	Animals ; Antineoplastic Agents/administration & dosage ; Antineoplastic Agents/therapeutic use ; Calcium-Binding Proteins ; Cysts/drug therapy ; Cysts/etiology ; Cysts/genetics ; Cysts/physiopathology ; DNA Helicases/genetics ; DNA Helicases/metabolism ; Disease Models, Animal ; Gene Expression Regulation, Neoplastic ; Glucosidases/genetics ; Glucosidases/metabolism ; Humans ; Intracellular Signaling Peptides and Proteins/genetics ; Intracellular Signaling Peptides and Proteins/metabolism ; Larva/metabolism ; Liver Diseases/drug therapy ; Liver Diseases/etiology ; Liver Diseases/genetics ; Liver Diseases/physiopathology ; Morpholinos/administration & dosage ; Morpholinos/metabolism ; Phenylbutyrates/administration & dosage ; Phenylbutyrates/therapeutic use ; Polycystic Kidney, Autosomal Dominant/drug therapy ; Polycystic Kidney, Autosomal Dominant/etiology ; Polycystic Kidney, Autosomal Dominant/genetics ; Polycystic Kidney, Autosomal Dominant/physiopathology ; Somatostatin/administration & dosage ; Somatostatin/analogs & derivatives ; Somatostatin/therapeutic use ; TRPP Cation Channels/genetics ; TRPP Cation Channels/metabolism ; Vitamin K 3/administration & dosage ; Vitamin K 3/therapeutic use ; Zebrafish
Chemical Substances	Antineoplastic Agents ; Calcium-Binding Proteins ; Intracellular Signaling Peptides and Proteins ; Morpholinos ; Phenylbutyrates ; TRPP Cation Channels ; polycystic kidney disease 1 protein ; Somatostatin (51110-01-1) ; Vitamin K 3 (723JX6CXY5) ; 4-phenylbutyric acid (7WY7YBI87E) ; pasireotide (98H1T17066) ; Glucosidases (EC 3.2.1.-) ; PRKCSH protein, human (EC 3.2.1.-) ; HFM1 protein, human (EC 3.6.1.-) ; DNA Helicases (EC 3.6.4.-)
Language	English
Publishing date	2013-05-13
Publishing country	United States
Document type	Journal Article ; Research Support, N.I.H., Extramural
ZDB-ID	2156020-1
ISSN	1557-8542 ; 1545-8547
ISSN (online)	1557-8542
ISSN	1545-8547
DOI	10.1089/zeb.2012.0825
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Physiology of cholangiocytes.

Tabibian, James H / Masyuk, Anatoliy I / Masyuk, Tetyana V / O'Hara, Steven P / LaRusso, Nicholas F

Comprehensive Physiology

2013 Volume 3, Issue 1, Page(s) 541–565

Abstract: Cholangiocytes are epithelial cells that line the intra- and extrahepatic ducts of the biliary tree. The main physiologic function of cholangiocytes is modification of hepatocyte-derived bile, an intricate process regulated by hormones, peptides, ... ...

Abstract	Cholangiocytes are epithelial cells that line the intra- and extrahepatic ducts of the biliary tree. The main physiologic function of cholangiocytes is modification of hepatocyte-derived bile, an intricate process regulated by hormones, peptides, nucleotides, neurotransmitters, and other molecules through intracellular signaling pathways and cascades. The mechanisms and regulation of bile modification are reviewed herein.
MeSH term(s)	Animals ; Bile/physiology ; Biliary Tract/physiology ; Epithelial Cells/physiology ; Humans ; Signal Transduction
Language	English
Publishing date	2013-05-29
Publishing country	United States
Document type	Journal Article ; Review
ISSN	2040-4603
ISSN (online)	2040-4603
DOI	10.1002/cphy.c120019
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Bacterial Cholangitis in Autosomal Dominant Polycystic Kidney and Liver Disease.

Martin, William P / Vaughan, Lisa E / Yoshida, Kotaro / Takahashi, Naoki / Edwards, Marie E / Metzger, Andrew / Senum, Sarah R / Masyuk, Tetyana V / LaRusso, Nicholas F / Griffin, Matthew D / El-Zoghby, Ziad / Harris, Peter C / Kremers, Walter K / Nagorney, David M / Kamath, Patrick S / Torres, Vicente E / Hogan, Marie C

Mayo Clinic proceedings. Innovations, quality & outcomes

2019 Volume 3, Issue 2, Page(s) 149–159

Abstract: Objective: To describe first episodes of bacterial cholangitis complicating autosomal dominant polycystic kidney disease (ADPKD) and autosomal dominant polycystic liver disease (ADPLD) and to identify risk factors for cholangitis episodes among patients ...

Abstract	Objective: To describe first episodes of bacterial cholangitis complicating autosomal dominant polycystic kidney disease (ADPKD) and autosomal dominant polycystic liver disease (ADPLD) and to identify risk factors for cholangitis episodes among patients with ADPKD-associated polycystic liver disease (PLD). Patients and methods: We searched the electronic medical records at our tertiary referral center for episodes of cholangitis in patients with ADPKD or ADPLD from January 1, 1996, through June 30, 2017. Cases were categorized as suspected or definite cholangitis by expert review. Clinical, laboratory, and radiologic data were manually abstracted. A nested case-control study was conducted to investigate risk factors for cholangitis in patients with ADPKD. Results: We identified 29 cases of definite or suspected cholangitis complicating PLD (24 with ADPKD-associated PLD and 5 with ADPLD). Among patients with definite cholangitis in ADPKD-associated PLD (n=19) vs ADPLD (n=4), the mean ± SD age was 62.4±12.2 vs 55.1±8.6 years, and 9 (47.4%) vs 0 (0%), respectively, were male. The odds of gallstones (odds ratio [OR], 21.6; 95% CI, 3.17-927; Conclusion: Gallstones, prior cholecystectomy, duodenal diverticulosis, type 2 diabetes mellitus, prior endoscopic retrograde cholangiopancreatography, and prior kidney transplant constituted risk factors for cholangitis among patients with ADPKD-associated PLD.
Language	English
Publishing date	2019-05-27
Publishing country	Netherlands
Document type	Journal Article
ISSN	2542-4548
ISSN (online)	2542-4548
DOI	10.1016/j.mayocpiqo.2019.03.004
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article: MicroRNAs and Benign Biliary Tract Diseases

Gradilone, Sergio A. / O'Hara, Steven P. / Masyuk, Tetyana V. / Pisarello, Maria Jose Lorenzo / LaRusso, Nicholas F.

Seminars in Liver Disease

(miRNA in Liver Pathobiology, Diagnosis, and Therapy)

2015 Volume 35, Issue 01, Page(s) 26–35

Abstract: Cholangiocytes, the epithelial cells lining the biliary tree, represent only a small portion of the total liver cell population (3–5%), but they are responsible for the secretion of up to 40% of total daily bile volume. In addition, cholangiocytes are ... ...

Series title	miRNA in Liver Pathobiology, Diagnosis, and Therapy
Abstract	Cholangiocytes, the epithelial cells lining the biliary tree, represent only a small portion of the total liver cell population (3–5%), but they are responsible for the secretion of up to 40% of total daily bile volume. In addition, cholangiocytes are the target of a diverse group of liver diseases affecting the biliary tract, the cholangiopathies; for most of these conditions, the pathological mechanisms are unclear. MicroRNAs (miRNAs) are small, noncoding RNAs that posttranscriptionally regulate gene expression. Thus, it is not surprising that altered miRNA profiles underlie the dysregulation of several proteins involved in the pathobiology of the cholangiopathies, as well as showing promise as diagnostic and prognostic tools. Here the authors review recent work relevant to the role of miRNAs in the etiopathogenesis of several of the cholangiopathies (i.e., fibroinflammatory cholangiopathies and polycystic liver diseases), discuss their value as prognostic and diagnostic tools, and provide suggestions for further research.
Keywords	cholangiocytes ; microRNAs ; cholangiopathies ; cholangiocarcinoma ; polycystic liver disease ; primary biliary cirrhosis ; primary sclerosing cholangitis ; biliary atresia
Language	English
Publishing date	2015-01-29
Publisher	Thieme Medical Publishers
Publishing place	Stuttgart ; New York
Document type	Article
ZDB-ID	603177-8
ISSN	1098-8971 ; 0272-8087
ISSN (online)	1098-8971
ISSN	0272-8087
DOI	10.1055/s-0034-1397346
Database	Thieme publisher's database

In stock of ZB MED Cologne/Königswinter

Zs.A 1752: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Somatostatin analog therapy for severe polycystic liver disease: results after 2 years.

Hogan, Marie C / Masyuk, Tetyana V / Page, Linda / Holmes, David R / Li, Xujian / Bergstralh, Eric J / Irazabal, Maria V / Kim, Bohyun / King, Bernard F / Glockner, James F / Larusso, Nicholas F / Torres, Vicente E

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association

2012 Volume 27, Issue 9, Page(s) 3532–3539

Abstract: Background: We showed in a randomized double-blinded placebo-controlled clinical trial that octreotide long-acting repeatable depot.® (OctLAR(®)) for 12 months reduces kidney and liver growth in autosomal dominant polycystic kidney patients with severe ... ...

Abstract	Background: We showed in a randomized double-blinded placebo-controlled clinical trial that octreotide long-acting repeatable depot.® (OctLAR(®)) for 12 months reduces kidney and liver growth in autosomal dominant polycystic kidney patients with severe polycystic liver disease (PLD) and liver growth in patients with severe isolated PLD. We have now completed an open-label extension for one additional year to assess safety and clinical benefits of continued use of OctLAR for 2 years (O → O) and examined drug effect in the placebo group who crossed over to OctLAR in Year 2 (P → O). Methods: The primary end point was change in total liver volume (TLV) measured by magnetic resonance imaging (MRI); secondary end points were changes in total kidney volume (TKV) measured by MRI, glomerular filtration rate (GFR), quality of life (QOL), safety, vital signs and laboratory parameters. Results: Forty-one of 42 patients received OctLAR (n = 28) or placebo (n = 14) in Year 1 and received OctLAR in Year 2 (maximum dose 40 mg). Patients originally randomized to placebo (P → O) showed substantial reduction in TLV after treatment with OctLAR in Year 2 (Δ% -7.66 ± 9.69%, P = 0.011). The initial reduction of TLV in the OctLAR group (O → O) was maintained for 2 years (Δ% -5.96 ± 8.90%), although did not change significantly during Year 2 (Δ% -0.77 ± 6.82%). OctLAR inhibited renal enlargement during Year 1 (Δ% +0.42 ± 7.61%) in the (O → O) group and during Year 2 (Δ% -0.41 ± 9.45%) in the (P → O) group, but not throughout Year 2 (Δ% +6.49 ± 7.08%) in the (O → O) group. Using pooled analyses of all individuals who received OctLAR for 12 months, i.e. in Year 1 for O → O patients and Year 2 for P → O patients, average reduction in TLV was -6.08 ± 7.58% (P = 0.001) compared to net growth of 0.9 ± 8.35% in the original placebo group. OctLAR-treated individuals continued to experience improvements in QOL in Year 2, although overall physical and mental improvements were not significant during Year 2 compared to Year 1. Changes in GFR were similar in both groups. Conclusion: Over 2 years, OctLAR significantly reduced the rate of increase in TLV and possibly the rate of increase in TKV.
MeSH term(s)	Adolescent ; Cross-Over Studies ; Cysts/complications ; Cysts/drug therapy ; Double-Blind Method ; Female ; Follow-Up Studies ; Glomerular Filtration Rate ; Hormones/therapeutic use ; Humans ; Kidney Diseases/etiology ; Kidney Diseases/pathology ; Liver Diseases/complications ; Liver Diseases/drug therapy ; Magnetic Resonance Imaging ; Male ; Prognosis ; Quality of Life ; Risk Factors ; Somatostatin/analogs & derivatives ; Somatostatin/therapeutic use ; Time Factors
Chemical Substances	Hormones ; Somatostatin (51110-01-1)
Language	English
Publishing date	2012-07-06
Publishing country	England
Document type	Clinical Trial ; Journal Article ; Randomized Controlled Trial ; Research Support, N.I.H., Extramural
ZDB-ID	90594-x
ISSN	1460-2385 ; 0931-0509
ISSN (online)	1460-2385
ISSN	0931-0509
DOI	10.1093/ndt/gfs152
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 2198: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 329: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease.

Hogan, Marie C / Masyuk, Tetyana V / Page, Linda J / Kubly, Vickie J / Bergstralh, Eric J / Li, Xujian / Kim, Bohyun / King, Bernard F / Glockner, James / Holmes, David R / Rossetti, Sandro / Harris, Peter C / LaRusso, Nicholas F / Torres, Vicente E

Journal of the American Society of Nephrology : JASN

2010 Volume 21, Issue 6, Page(s) 1052–1061

Abstract: There are no proven, effective therapies for polycystic kidney disease (PKD) or polycystic liver disease (PLD). We enrolled 42 patients with severe PLD resulting from autosomal dominant PKD (ADPKD) or autosomal dominant PLD (ADPLD) in a randomized, ... ...

Abstract	There are no proven, effective therapies for polycystic kidney disease (PKD) or polycystic liver disease (PLD). We enrolled 42 patients with severe PLD resulting from autosomal dominant PKD (ADPKD) or autosomal dominant PLD (ADPLD) in a randomized, double-blind, placebo-controlled trial of octreotide, a long-acting somatostatin analogue. We randomly assigned 42 patients in a 2:1 ratio to octreotide LAR depot (up to 40 mg every 28+/-5 days) or placebo for 1 year. The primary end point was percent change in liver volume from baseline to 1 year, measured by MRI. Secondary end points were changes in total kidney volume, GFR, quality of life, safety, vital signs, and clinical laboratory tests. Thirty-four patients had ADPKD, and eight had ADPLD. Liver volume decreased by 4.95%+/-6.77% in the octreotide group but remained practically unchanged (+0.92%+/-8.33%) in the placebo group (P=0.048). Among patients with ADPKD, total kidney volume remained practically unchanged (+0.25%+/-7.53%) in the octreotide group but increased by 8.61%+/-10.07% in the placebo group (P=0.045). Changes in GFR were similar in both groups. Octreotide was well tolerated; treated individuals reported an improved perception of bodily pain and physical activity. In summary, octreotide slowed the progressive increase in liver volume and total kidney volume, improved health perception among patients with PLD, and had an acceptable side effect profile.
MeSH term(s)	Adult ; Aged ; Double-Blind Method ; Female ; Glomerular Filtration Rate/drug effects ; Humans ; Kidney/drug effects ; Kidney/pathology ; Kidney/physiopathology ; Liver/drug effects ; Liver/enzymology ; Liver/pathology ; Liver Diseases/drug therapy ; Liver Diseases/physiopathology ; Male ; Middle Aged ; Octreotide/adverse effects ; Octreotide/pharmacology ; Octreotide/therapeutic use ; Organ Size/drug effects ; Polycystic Kidney, Autosomal Dominant/drug therapy ; Polycystic Kidney, Autosomal Dominant/physiopathology ; Somatostatin/analogs & derivatives ; Treatment Outcome
Chemical Substances	Somatostatin (51110-01-1) ; Octreotide (RWM8CCW8GP)
Language	English
Publishing date	2010-04-29
Publishing country	United States
Document type	Journal Article ; Randomized Controlled Trial
ZDB-ID	1085942-1
ISSN	1533-3450 ; 1046-6673
ISSN (online)	1533-3450
ISSN	1046-6673
DOI	10.1681/ASN.2009121291
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 3344: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito